Age is no barrier to tolerability or efficacy of radioembolization for colorectal liver metastases

Here is my highlight from the december issue of HPB

Radioembolization is still searching for its precise niche in the armoury of treatments for colorectal liver metastases. The majority of protocols advise its use in patients who have non-resectable and chemotherapy-resistant liver metastases with some requiring failure of first line chemotherapy and some second line chemotherapy. Guidance on its use in patients with extrahepatic sites of disease is also somewhat variable. Economic considerations influence patient selection in a number of healthcare models in addition to outcome data.

In this edition of HPBTohme and colleagues from the University of Pittsburgh explore outcomes of older patients treated with radioembolization. They have reported outcomes of more than 100 patients older or younger than 70 years treated with one or more episodes of radioembolization for non-resectable liver metastases which have proved resistant to one or two chemotherapy regimens. Fatigue is a frequently reported complicating symptom of radioembolization. It might be considered that elderly patients have less physical reserve. However, the Pittsburgh group found no difference in either frequency or severity of fatigue in treated patients based on age. Other side effect profiles were also similar suggesting that this treatment modality is well tolerated by the elderly. In terms of patient survival, again there was no difference in outcome based on patient age. The major determinant of poor outcome appeared to be the presence of extrahepatic disease but this was the same irrespective of age.

This article provides evidence that radioembolization is effective and reasonably well tolerated in patients with colorectal liver metastases and should be considered in motivated patients regardless of age.

Survival and tolerability of liver radioembolization: a comparison of elderly and younger patients with metastatic colorectal cancer

  1. Samer Tohme1,
  2. Daniel Sukato1,
  3. Gary W Nace1,
  4. Albert Zajko2,
  5. Nikhil Amesur2,
  6. Philip Orons2,
  7. Didier Chalhoub3,
  8. James W Marsh1,
  9. David A Geller1 and
  10. Allan Tsung
HPB

HPB

Volume 16Issue 12pages 1110–1116December 2014

SIRT copyPicture from Macmillan cancer organisation

Further patient information at http://www.macmillan.org.uk/Cancerinformation/Cancertreatment/Treatmenttypes/Radiotherapy/Internalradiotherapy/SIRT.aspx

Advertisements
This entry was posted in General. Bookmark the permalink.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s